TrialCancer chemotherapy and pharmacology2019

Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.

Robin L Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.